We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Mallinckrodt plc Reports Third Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire DUBLIN, Nov. 5, 2024 Achieves Third Quarter Net Sales of $505.5 Million, Reflecting...
Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection at the 2024 American Association for the Study of Liver Diseases (AASLD) Annual Meeting PR Newswire DUBLIN, Oct. 30, 2024 –...
Mallinckrodt Announces an Expanded Rollout of the INOmax® EVOLVE™ DS Delivery System in U.S. Hospitals PR Newswire DUBLIN, Oct. 10, 2024 – The INOmax EVOLVE DS is our next-generation nitric...
Mallinckrodt Announces Publication of Human Factors Studies and Arthritis Foundation Ease of Use® Certification of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled...
THERAKOS™ CELLEX™ Photopheresis System Receives CE Certificate Under the European Union Medical Device Regulation (EU MDR) PR Newswire DUBLIN, Sept. 3, 2024 – THERAKOS, the world's only fully...
Mallinckrodt plc Reports Second Quarter 2024 Financial Results and Raises Full Year Guidance PR Newswire DUBLIN, Aug. 6, 2024 Achieves Second Quarter Net Sales of $514.3 Million, Reflecting...
Mallinckrodt Announces Availability of Acthar® Gel (repository corticotropin injection) Single-Dose Pre-filled SelfJect™ Injector in the U.S. PR Newswire DUBLIN, Aug. 6, 2024 – Acthar Gel is the...
Mallinckrodt Reaches Agreement to Sell Therakos® Business to CVC for $925 Million PR Newswire DUBLIN and LUXEMBOURG, Aug. 5, 2024 Divestiture Advances Mallinckrodt's Strategic Priorities to...
Mallinckrodt to Report Earnings Results for Second Quarter 2024 PR Newswire DUBLIN, Aug. 1, 2024 DUBLIN, Aug. 1, 2024 /PRNewswire/ -- Mallinckrodt plc ("Mallinckrodt" or the "Company"), a global...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions